KNSA vs. RCUS, ANIP, DAWN, XNCR, MORF, PTGX, AKRO, DVAX, GMTX, and LGND
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Xencor (XNCR), Morphic (MORF), Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Dynavax Technologies (DVAX), Gemini Therapeutics (GMTX), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 12.3% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Kiniksa Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 58.73%. Arcus Biosciences has a consensus target price of $41.25, indicating a potential upside of 146.86%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Arcus Biosciences' net margin of -97.47%. Kiniksa Pharmaceuticals' return on equity of -7.26% beat Arcus Biosciences' return on equity.
Arcus Biosciences received 16 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 64.54% of users gave Arcus Biosciences an outperform vote while only 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote.
Kiniksa Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
In the previous week, Arcus Biosciences had 17 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 22 mentions for Arcus Biosciences and 5 mentions for Kiniksa Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.63 beat Kiniksa Pharmaceuticals' score of 0.31 indicating that Arcus Biosciences is being referred to more favorably in the news media.
Summary
Kiniksa Pharmaceuticals and Arcus Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
